Post by luxetvox on Feb 14, 2023 14:43:24 GMT
Looks like Quest is also focused on lab partnerships. They just inked one with a big brand name:
Quest Diagnostics and NewYork-Presbyterian Agree to Laboratory Services
Transaction
PR Newswire
SECAUCUS, N.J. and NEW YORK, Feb. 14, 2023
Goal to serve NewYork-Presbyterian's providers and patients in the greater New
York region and beyond
SECAUCUS, N.J. and NEW YORK, Feb. 14, 2023 /PRNewswire/ -- Quest Diagnostics
(NYSE: DGX), the world's leading provider of diagnostic information services,
and NewYork-Presbyterian, one of the nation's largest and most comprehensive
academic medical centers, today announced a strategic agreement designed to
broaden access to quality, innovative laboratory services for the providers
and patients of NewYork-Presbyterian primarily in New York as well as the
Tri-State Area and beyond.
Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics
Incorporated)
Under a definitive agreement, Quest will acquire select assets of the
laboratory services business of NewYork-Presbyterian. NewYork-Presbyterian
will still own and operate world-renowned hospital labs, including its
anatomic pathology services, to continue providing high quality, complex
clinical laboratory services with its academic partners.
"NewYork-Presbyterian and Quest share a belief that exceptional patient care
should be accessible to all," said Steven J. Corwin, MD, President and CEO of
NewYork-Presbyterian. "We determined that working with Quest would be the best
path – allowing our patients wider access to advanced, quality laboratory
services."
"NewYork-Presbyterian and Quest share much in common, including a keen focus
on the patient, deep roots in New York and reputations nationwide and beyond
for outstanding healthcare services," said Jim Davis, CEO and President, Quest
Diagnostics. "We also both recognize the foundational role of laboratory
medicine to healthcare. Our agreement with NewYork-Presbyterian is designed to
leverage Quest's ability to deliver clinical laboratory services with
outstanding innovation and quality."
The parties expect to complete the transaction in the second quarter of 2023,
pending customary regulatory approvals. Financial details of the transaction
were not disclosed.
Quest Diagnostics and NewYork-Presbyterian Agree to Laboratory Services
Transaction
PR Newswire
SECAUCUS, N.J. and NEW YORK, Feb. 14, 2023
Goal to serve NewYork-Presbyterian's providers and patients in the greater New
York region and beyond
SECAUCUS, N.J. and NEW YORK, Feb. 14, 2023 /PRNewswire/ -- Quest Diagnostics
(NYSE: DGX), the world's leading provider of diagnostic information services,
and NewYork-Presbyterian, one of the nation's largest and most comprehensive
academic medical centers, today announced a strategic agreement designed to
broaden access to quality, innovative laboratory services for the providers
and patients of NewYork-Presbyterian primarily in New York as well as the
Tri-State Area and beyond.
Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics
Incorporated)
Under a definitive agreement, Quest will acquire select assets of the
laboratory services business of NewYork-Presbyterian. NewYork-Presbyterian
will still own and operate world-renowned hospital labs, including its
anatomic pathology services, to continue providing high quality, complex
clinical laboratory services with its academic partners.
"NewYork-Presbyterian and Quest share a belief that exceptional patient care
should be accessible to all," said Steven J. Corwin, MD, President and CEO of
NewYork-Presbyterian. "We determined that working with Quest would be the best
path – allowing our patients wider access to advanced, quality laboratory
services."
"NewYork-Presbyterian and Quest share much in common, including a keen focus
on the patient, deep roots in New York and reputations nationwide and beyond
for outstanding healthcare services," said Jim Davis, CEO and President, Quest
Diagnostics. "We also both recognize the foundational role of laboratory
medicine to healthcare. Our agreement with NewYork-Presbyterian is designed to
leverage Quest's ability to deliver clinical laboratory services with
outstanding innovation and quality."
The parties expect to complete the transaction in the second quarter of 2023,
pending customary regulatory approvals. Financial details of the transaction
were not disclosed.